See Supplemental Patient Information
- Elderly patients with dementia-related psychosis are at an increased risk of death when treated with antipsychotic drugs. Trifluoperazine hydrochloride is not approved for the treatment of patients with dementia-related psychosis [US Black Box Warning]
- Therapy may develop Tardive dyskinesia showing irreversible, involuntary, dyskinetic movements
- It may develop Neuroleptic Malignant Syndrome (NMS). Immediately discontinue therapy after early signs and symptoms of NMS. Institute symptomatic treatment and closely monitor patients for other concomitant serious medical problem
- Reintroduction of drug therapy should be carefully considered. Closely monitor patients, since recurrences of NMS have been reported
- Concomitant administration of lithium may develop encephalopathic syndrome followed by irreversible brain damage. Monitor closely for early evidence of neurologic toxicity and discontinue promptly if such signs appear
- Caution advised about activities requiring alertness as therapy may impair mental or physical abilities
- There is possibility of an undesirable additive depressant effect if sedatives, narcotics, anesthetics, tranquilizers or alcohol are used either simultaneously or successively with the drug
- Monitor hematological changes for thrombocytopenia and anemia
- Stop therapy if fever with grippe-like symptoms occurs. It may cause jaundice of the cholestatic type of hepatitis or liver damage
- Monitor angina patients carefully for an unfavorable response as few patients have experienced increased pain while taking the drug
- If hypotension occurs, place patient in head-low position with legs raised and institute proper treatment
- Perform periodic ophthalmoscopic examination during therapy as it may produce retinopathy. Avoid use in glaucoma as administration may cause mydriasis
- It may produce false-positive phenylketonuria (PKU) test results
- Use with caution in persons who will be exposed to extreme heat because drug may interfere with thermoregulatory mechanisms
- Reduce maintenance dose or discontinue therapy in patients with a history of long-term therapy with trifluoperazine hydrochloride or other antipsychotics to lessen the possible adverse reactions
Cautions: Use cautiously in
- Elderly patients
- Cardiovascular disorder
- Occular disease
- Sodium bisulfite allergy (concentrate dose form)
Supplemental Patient Information
- Advise patients to notify their physician if they become pregnant or intent to become pregnant during treatment with an antipsychotic agent, but not abruptly discontinue therapy without physician's recommendation
Pregnancy category: C; neonates exposed to antipsychotic agents during last trimester of pregnancy are at an increased risk of developing extrapyramidal and withdrawal symptoms following birth.
Breastfeeding: Safety Unknown. Use cautiously only when the potential benefits clearly outweigh possible hazards.
US Trade Name(s)
US Availability
trifluoperazine (generic)
Canadian Trade Name(s)
- Terfluzine
- Novo-Trifluzine
- Terfluzine concentrate
Canadian Availability
trifluoperazine (generic)
- SYRUP: 1, 10 mg/mL
- TABS: 2, 5, 10, 20 mg
Terfluzine
Novo-Trifluzine
Terfluzine concentrate
UK Trade Name(s)
UK Availability
trifluoperazine (generic)
Stelazine
- SYRUP: 1 mg/5 mL
- TABS: 1, 5 mg
Australian Trade Name(s)
Australian Availability
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Trifluoperazine HCl 2 MG TABS [Bottle] (MYLAN)
60 mg = $36.99
180 mg = $86.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
